Literature DB >> 28713019

Glioma sensitive or chemoresistant to temozolomide differentially modulate macrophage protumor activities.

Juliana H Azambuja1, Elita F da Silveira2, Taíse R de Carvalho3, Pathise S Oliveira3, Simone Pacheco3, Carlus T do Couto3, Fátima T Beira4, Francieli M Stefanello3, Rosélia M Spanevello3, Elizandra Braganhol5.   

Abstract

BACKGROUND: Glioblastomas are the most devastating brain tumor characterized by chemoresistance development and poor prognosis. Macrophages are a component of tumor microenvironment related to glioma malignancy. The relation among inflammation, innate immunity and cancer is accepted; however, molecular and cellular mechanisms mediating this relation and chemoresistance remain unresolved.
OBJECTIVE: Here we evaluated whether glioma sensitive or resistant to temozolomide (TMZ) modulate macrophage polarization and inflammatory pathways associated. The impact of glioma-macrophage crosstalk on glioma proliferation was also investigated.
METHODS: GL261 glioma chemoresistance was developed by exposing cells to increasing TMZ concentrations over a period of 6months. Mouse peritoneal macrophages were exposed to glioma-conditioned medium or co-cultured directly with glioma sensitive (GL) or chemoresistant (GLTMZ). Macrophage polarization, in vitro and in vivo glioma proliferation, redox parameters, ectonucleotidase activity and ATP cytotoxicity were performed.
RESULTS: GLTMZ cells were more effective than GL in induce M2-like macrophage polarization and in promote a strong immunosuppressive environment characterized by high IL-10 release and increased antioxidant potential, which may contribute to glioma chemoresistance and proliferation. Interestingly, macrophage-GLTMZ crosstalk enhanced in vitro and in vivo proliferation of chemoresistant cells, decreased ectonucleotidase activities, which was followed by increased macrophage sensitivity to ATP induced death.
CONCLUSIONS: Results suggest a differential macrophage modulation by GLTMZ cells, which may favor the maintenance of immunosuppressive tumor microenvironment and glioma proliferation. GENERAL SIGNIFICANCE: The induction of immunosuppressive environment and macrophage education by chemoresistant gliomas may be important for tumor recovery after chemotherapy and could be considered to overcome chemoresistance development.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Chemoresistance; Gliomas; Inflammation; Macrophage; Purinergic system; Temozolomide

Mesh:

Substances:

Year:  2017        PMID: 28713019     DOI: 10.1016/j.bbagen.2017.07.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta Gen Subj        ISSN: 0304-4165            Impact factor:   3.770


  17 in total

1.  Blockade of CD73 delays glioblastoma growth by modulating the immune environment.

Authors:  J H Azambuja; R S Schuh; L R Michels; I C Iser; L R Beckenkamp; G G Roliano; G S Lenz; J N Scholl; J Sévigny; M R Wink; M A Stefani; A M O Battastini; F Figueiró; H F Teixeira; E Braganhol
Journal:  Cancer Immunol Immunother       Date:  2020-04-29       Impact factor: 6.968

2.  Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach.

Authors:  J H Azambuja; R S Schuh; L R Michels; N E Gelsleichter; L R Beckenkamp; I C Iser; G S Lenz; F H de Oliveira; G Venturin; S Greggio; J C daCosta; M R Wink; J Sevigny; M A Stefani; A M O Battastini; H F Teixeira; E Braganhol
Journal:  Mol Neurobiol       Date:  2019-08-12       Impact factor: 5.590

3.  Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia.

Authors:  Weiqi Dang; Jingfang Xiao; Qinghua Ma; Jingya Miao; Mianfu Cao; Lu Chen; Yu Shi; Xiaohong Yao; Shichang Yu; Xindong Liu; Youhong Cui; Xia Zhang; Xiuwu Bian
Journal:  Brain Tumor Pathol       Date:  2021-07-06       Impact factor: 3.298

4.  [Establishment of a mouse model bearing orthotopic temozolomide-resistant glioma].

Authors:  Linyong Shi; Hong Li; Junwei Gu; Chong Song; Junjie Li; Lei Chen; Qiang Zhou; Songtao Qi; Yuntao Lu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-01-30

5.  Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma.

Authors:  Dipongkor Saha; Samuel D Rabkin; Robert L Martuza
Journal:  J Immunother Cancer       Date:  2020-05       Impact factor: 13.751

6.  Arginase-1+ Exosomes from Reprogrammed Macrophages Promote Glioblastoma Progression.

Authors:  Juliana H Azambuja; Nils Ludwig; Saigopalakrishna S Yerneni; Elizandra Braganhol; Theresa L Whiteside
Journal:  Int J Mol Sci       Date:  2020-06-02       Impact factor: 5.923

7.  Molecular profiles and immunomodulatory activities of glioblastoma-derived exosomes.

Authors:  Juliana Hofstatter Azambuja; Nils Ludwig; Saigopalakrishna Yerneni; Aparna Rao; Elizandra Braganhol; Theresa L Whiteside
Journal:  Neurooncol Adv       Date:  2020-05-06

Review 8.  Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity.

Authors:  Juliana Hofstätter Azambuja; Nils Ludwig; Elizandra Braganhol; Theresa L Whiteside
Journal:  Int J Mol Sci       Date:  2019-11-14       Impact factor: 5.923

9.  Molecular Characterization of Temozolomide-Treated and Non Temozolomide-Treated Glioblastoma Cells Released Extracellular Vesicles and Their Role in the Macrophage Response.

Authors:  Elisa Panzarini; Stefano Tacconi; Elisabetta Carata; Stefania Mariano; Ada Maria Tata; Luciana Dini
Journal:  Int J Mol Sci       Date:  2020-11-07       Impact factor: 5.923

10.  Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models.

Authors:  Silvia Valtorta; Alessia Lo Dico; Luisa Ottobrini; Rosa Maria Moresco; Isabella Raccagni; Daniela Gaglio; Sara Belloli; Letterio S Politi; Cristina Martelli; Cecilia Diceglie; Marcella Bonanomi; Giulia Ercoli; Valentina Vaira
Journal:  Oncotarget       Date:  2017-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.